Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Bono

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
International Journal of Oncology|April 11, 2001
Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotidesS Agrawal, E R Kandimalla, D Yu, et al.
British Journal of Cancer|May 5, 2011
Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II studyH Joensuu, F De Braud, G Grignagni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2009
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trialH Joensuu, L Sailas, T Alanko, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 3, 2011
Very high quantitative tumor HER2 content and outcome in early breast cancerH Joensuu, J Sperinde, M Leinonen, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|December 28, 2002
Characterization of dendritic cells generated in vivo by an E. coli derived chimeric dual receptor agonistLarry E Kahn, Parul D Doshi, Kelly L McGarity, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2014
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trialS Loi, S Michiels, R Salgado, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1997
A peptidomimetic that specifically inhibits human leukocyte antigen DRB1*0401-restricted T cell proliferationS L Woulfe, C P Bono, M L Zacheis, et al.
Journal of Medical Genetics|September 6, 2005
The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neckP Alhopuro, S K Ylisaukko-Oja, W J Koskinen, et al.
Bioorganic & Medicinal Chemistry Letters|May 2, 2012
Investigation of the binding pocket of human hematopoietic prostaglandin (PG) D2 synthase (hH-PGDS): a tale of two watersJohn I Trujillo, James R Kiefer, Wei Huang, et al.
The Journal of Toxicological Sciences|March 1, 2021
Microphysiological systems in early stage drug development: Perspectives on current applications and future impactAnna K Kopec, Ryuji Yokokawa, Nasir Khan, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
International Journal of Oncology|April 11, 2001
Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotidesS Agrawal, E R Kandimalla, D Yu, et al.
British Journal of Cancer|May 5, 2011
Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II studyH Joensuu, F De Braud, G Grignagni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2009
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trialH Joensuu, L Sailas, T Alanko, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 3, 2011
Very high quantitative tumor HER2 content and outcome in early breast cancerH Joensuu, J Sperinde, M Leinonen, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|December 28, 2002
Characterization of dendritic cells generated in vivo by an E. coli derived chimeric dual receptor agonistLarry E Kahn, Parul D Doshi, Kelly L McGarity, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 11, 2014
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trialS Loi, S Michiels, R Salgado, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1997
A peptidomimetic that specifically inhibits human leukocyte antigen DRB1*0401-restricted T cell proliferationS L Woulfe, C P Bono, M L Zacheis, et al.
Journal of Medical Genetics|September 6, 2005
The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neckP Alhopuro, S K Ylisaukko-Oja, W J Koskinen, et al.
Bioorganic & Medicinal Chemistry Letters|May 2, 2012
Investigation of the binding pocket of human hematopoietic prostaglandin (PG) D2 synthase (hH-PGDS): a tale of two watersJohn I Trujillo, James R Kiefer, Wei Huang, et al.
The Journal of Toxicological Sciences|March 1, 2021
Microphysiological systems in early stage drug development: Perspectives on current applications and future impactAnna K Kopec, Ryuji Yokokawa, Nasir Khan, et al.
Pageof 6